NEW YORK (TheStreet) -- Shares of iBio (IBIO) - Get Report  spiked again, up 20.64% to $2.28, in morning trading Friday as the Ebola outbreak continues.

The company announced Thursday it had offered to aid the U.S. government by offering its proprietary antibody production technology to help deal with the ongoing Ebola virus outbreak.

The company responded to shareholder and media questions in a statement on Thursday and referred to its collaboration with Caliber Biotherapeutics. iBio said the "superior homogeneity of antibody glysolylation," or the addition of sugars to proteins, in plants could have significant efficacy advantages compared to similar antibodies produced in Chinese hamster ovary (CHO) cells.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

iBio said it would offer its assistance to the federal government by offering its proprietary technology "for emergency use to enable the manufacture and yield optimization of certain experimental antibody-based drugs that address the current Ebola virus outbreak."

Image placeholder title

IBIO

data by

YCharts

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.